ArticlePloS one2016
Characterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Pooled it
- Probiotic Yeasts and Bacteria: A Complementary Approach to Gut Health.Microorganisms · 2026Review
- Metal-Organic Frameworks in Food Biotechnology: Opportunities, Challenges, and Future Perspectives for Probiotic Delivery, Precision Fermentation, and Circular Food Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- Current Understanding of Probiotic Strains and Immune Function: From Gut Microbiota to Systemic Immunity.International journal of molecular sciences · 2026Review
- Article
- Molecular Genetics and Probiotic Mechanisms of Saccharomyces cerevisiae var. boulardii.Probiotics and antimicrobial proteins · 2026Review
- A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation.Disease models & mechanisms · 2026Article
- Genomic and phenotypic comparison ofbioRxiv : the preprint server for biology · 2025Article
- Enabling technologies for in situ biomanufacturing using probiotic yeast.Advanced drug delivery reviews · 2025Review
- Development of a Dihydrofolate Reductase Selection System forInternational journal of molecular sciences · 2025Article
- Investigation of impact of siderophore and process variables on production of iron enriched Saccharomyces boulardii by Plackett-Burman design.Scientific reports · 2024Article
- Novel Insights in the Application of Probiotic YeastFoods (Basel, Switzerland) · 2024Review
- A Comparative Study of Composition and Soluble Polysaccharide Content between Brewer's Spent Yeast and Cultured Yeast Cells.Foods (Basel, Switzerland) · 2024Article
- Production of iron enriched Saccharomyces boulardii: impact of process variables.Scientific reports · 2024Article
- New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.Applied microbiology and biotechnology · 2024Article
- The effects of ultrasonic processing on the antioxidant activity ofFrontiers in nutrition · 2024Article
- Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.Cureus · 2023Review
- Investigating the Efficacy ofInternational journal of molecular sciences · 2023Review
- Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach.Microbial cell factories · 2023Article
- Yeast oral vaccines against infectious diseases.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The probiotic yeast Saccharomyces boulardii has been shown to ameliorate disease severity in the context of many infectious and inflammatory conditions. However, use of S. boulardii as a prophylactic agent or therapeutic delivery vector would require delivery of S. boulardii to a healthy, uninflamed intestine. In contrast to inflamed mucosal tissue, the diverse microbiota, intact epithelial barrier, and fewer inflammatory immune cells within the healthy intestine may all limit the degree to which S. boulardii contacts and influences the host mucosal immune system. Understanding the nature of these interactions is crucial for application of S. boulardii as a prophylactic agent or therapeutic delivery vehicle. In this study, we explore both intrinsic and immunomodulatory properties of S. boulardii in the healthy mucosal immune system. Genomic sequencing and morphological analysis of S. boulardii reveals changes in cell wall components compared to non-probiotic S. cerevisiae that may partially account for probiotic functions of S. boulardii. Flow cytometry and immunohistochemistry demonstrate limited S. boulardii association with murine Peyer's patches. We also show that although S. boulardii induces a systemic humoral immune response, this response is small in magnitude and not directed against S. boulardii itself. RNA-seq of the draining mesenteric lymph nodes indicates that even repeated administration of S. boulardii induces few transcriptional changes in the healthy intestine. Together these data strongly suggest that interaction between S. boulardii and the mucosal immune system in the healthy intestine is limited, with important implications for future work examining S. boulardii as a prophylactic agent and therapeutic delivery vehicle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.